Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 61 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging BiomarkersActive, not recruitingNCT04946968Phase 2
• A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04946890Phase 1/2
• Safety and Effectivness of Quercetin & Dasatinib on Epigenetic AgingStatus unknownNCT04946383Phase 2
• Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPAStatus unknownNCT04944524Phase 4
• Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisStatus unknownNCT04944069Not applicable
• A Study of TQ05105 in Patients With Chronic Graft Versus Host DiseaseActive, not recruitingNCT04944043Phase 1/2
• A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)TerminatedNCT04941404Phase 1/2
• Dedicated Drug-Drug Interaction (DDI) Study in Healthy VolunteersCompletedNCT04939467Phase 1
• A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;CompletedNCT04939363Phase 2
• Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingNCT04938817Phase 1/2
• A Study of NB003 in Patients With Advanced MalignanciesCompletedNCT04936178Phase 1
• A Study to Explore the Effect of Acid-reducing AgentsCompletedNCT04935112Phase 1
• The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP PatientsStatus unknownNCT04933526Phase 4
• Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung CancerStatus unknownNCT04933175Phase 2
• SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular CarcinomaCompletedNCT04930315Phase 2
• Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal CancerStatus unknownNCT04929652Phase 1/2
• The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid ArthritisStatus unknownNCT04927000Phase 4
• Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04926532Phase 1/2
• Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis ManagementActive, not recruitingNCT04925973Phase 2
• A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)CompletedNCT04925141Phase 4
• A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung CancerTerminatedNCT04924192Phase 2
• Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT04923945Phase 3
• Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedNCT04923932Phase 2
• Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsActive, not recruitingNCT04923906Phase 3
• Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung CancerActive, not recruitingNCT04922658Phase 2
• Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCActive, not recruitingNCT04919811Phase 2
• Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaCompletedNCT04919642Phase 2
• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingNCT04917809Phase 2
• A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome PatientsCompletedNCT04916756Phase 1/2
• A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196CompletedNCT04914936Phase 1
• Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCCStatus unknownNCT04911959Phase 1/2
• Surufatinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT04910854Phase 2
• Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult ParticipantsCompletedNCT04909242Phase 1
• Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)TerminatedNCT04908956Phase 2
• Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell TransplantTerminatedNCT04908735Phase 2
• A Drug-drug Interaction Study of Avapritinib and MidazolamCompletedNCT04908176Phase 1
• Acalabrutinib in CNSLActive, not recruitingNCT04906902Phase 1/2
• Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLCStatus unknownNCT04905550Phase 2
• A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedNCT04905043Phase 1
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell CancerTerminatedNCT04904302Phase 2
• Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerCompletedNCT04903652Phase 2
• A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy ParticipantsCompletedNCT04901923Phase 1
• Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid TumorsTerminatedNCT04901806Phase 1
• Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerStatus unknownNCT04901754Phase 2
• Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)CompletedNCT04901325Phase 2
• Fulvestrant + Neratinib In Breast CancerWithdrawnNCT04901299Phase 2
• Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell LymphomaStatus unknownNCT04899570Phase 2
• Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
• Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04899427Phase 2
• Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.WithdrawnNCT04896320Phase 1/2
• Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCStatus unknownNCT04895930Phase 2
• TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT04891900Not applicable
• EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform TrialTerminatedNCT04891133Phase 2/3
• A Phase Ib / IIA Study of AL8326 in Small Cell Lung CancerStatus unknownNCT04890795Phase 1/2
• A Phase I Study of AL8326 in Advanced Solid TumorStatus unknownNCT04890587Phase 1
• To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT04888715Phase 1
• Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaCompletedNCT04888429Phase 2
• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesCompletedNCT04887194Phase 1
• Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)Active, not recruitingNCT04886804Phase 1
• Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
• Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib TreatmentStatus unknownNCT04882345Phase 2
• Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Phase 2
• SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyStatus unknownNCT04878107Phase 2
• The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
• A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With OmeprazoleCompletedNCT04876807Phase 1
• A Phase II Trial of Cabozantinib With Patients With Refractory GCTsCompletedNCT04876456Phase 2
• Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenibCompletedNCT04874207Phase 4
• TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)TerminatedNCT04873895Phase 1
• Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerActive, not recruitingNCT04872985Phase 2
• Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
• Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesStatus unknownNCT04870190Phase 3
• A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult ParticipantsCompletedNCT04867980Phase 1
• A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196CompletedNCT04867941Phase 1
• A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous ChemotherapyStatus unknownNCT04866108Phase 2
• Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the StomachWithdrawnNCT04863430Phase 2
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
• The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or ParagangliomaCompletedNCT04860700Phase 2
• Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingNCT04859946Phase 2
• Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion MutationCompletedNCT04858958Phase 1
• Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast CancerWithdrawnNCT04856475Phase 2
• Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)CompletedNCT04856293Phase 1
• Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 PneumoniaStatus unknownNCT04856111Phase 4
• A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal CancerActive, not recruitingNCT04854668Phase 3
• Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell LymphomaActive, not recruitingNCT04850495Phase 1
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
• Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
• Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult SubjectsCompletedNCT04843540Phase 1
• MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)Active, not recruitingNCT04841811Phase 3
• BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)CompletedNCT04839471Phase 2
• Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell TransplantationCompletedNCT04838704Not applicable
• Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingNCT04837716Phase 1
• Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
• A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With OsteosarcomaCompletedNCT04833582Phase 1
• Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver MetastasesStatus unknownNCT04832204Phase 2
• Dasatinib for the Treatment of Moderate and Severe COVID-19WithdrawnNCT04830735Phase 2
• Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous UrticariaWithdrawnNCT04827589Phase 2
• A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)CompletedNCT04827069Phase 1
• A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell LymphomaStatus unknownNCT04827004Phase 2

← Tyrosine Kinase Inhibitors overview